HTLV-1 is a global infection with 5-20 million infected individuals. Although only a minority of
infected individuals develop myelopathy, lymphoproliferative malignancy, or inflammatory …

The 2022 annual meeting of the HTLV & HIV‐2 Spanish Network was held in Madrid on
December 14. We summarize here the main information presented and discussed at the …

Background A link between chronic inflammation and several noncommunicable diseases
(NCDs) has been established. Although chronic infection with the human T-cell leukemia …

In 2012, the number of people infected with human T cell lymphotropic virus type 1 (HTLV-1)
was estimated to be 10 million worldwide. Prevalence varies according to geographic …

HIV pre-exposure prophylaxis (HIV-PrEP) is effective in reducing the likelihood of HIV
acquisition in HIV-negative people at high risk of exposure. Guidelines recommend testing …

Background Central Australia has the highest recorded prevalence of infection with the
human T cell leukaemia virus type 1 (HTLV-1) worldwide. Each of the clinical diseases …

HTLV-1 can cause serious diseases such as adult T-cell leukemia (ATL) in humans after
chronic asymptomatic latent infection with substantial proviral load. Proviruses are …

Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus associated with substantial risk
of secondary (often life-threatening) disease for the estimated 10 million to 20 million people …

In central Australia, an area that is endemic for the human T-cell leukaemia virus type-1
(HTLV-1), the prevalence of Strongyloides stercoralis and its association with other health …

Human T cell leukemia/T-lymphotropic virus type 1 (HTLV-1) infection occurs by cell-to-cell
transmission and can induce fatal adult T cell leukemia. Vaccine development is critical for …